Aldeyra Therapeutics, Inc. Class Action Lawsuit - ALDX

The filed complaint alleges that Aldeyra Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the ADX-2191 new drug application ("NDA") did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the ALDX class action lawsuit, you must have incurred a loss on shares of Aldeyra purchased during the class period listed above.

If you suffered a loss in Aldeyra during the relevant time frame or pursuant to the relevant offering(s), you have until September 29, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.